Business Development

QED Bioscience is actively seeking to partner with companies that have targets to which they would like to generate either polyclonal or monoclonal antibodies. QED Bioscience considers itself a partner with its clients with an objective of generating the highest quality antibodies for use in your research, diagnostic, or drug discovery applications. QED Bioscience’s facilities and highly experienced staff are prepared to accommodate the needs of its clients in order to provide them with the high quality antibody product that they expect. QED’s experience, speed, and flexibility is designed to assist our clients by reducing the time to publication, market, or target screening and selection.

QED Bioscience is actively pursuing partner development programs in three fashions.

1. QED will develop monoclonal or polyclonal antibodies to your targets of interest. All antibodies and other materials developed belong solely to the client for use in their research.



2. QED Bioscience will work with its partners who have targets of interest to QED Bioscience to develop high quality monoclonal antibodies at no cost to the partner. Once developed, QED Bioscience will include the antibody in the QED Bioscience catalog, providing antibody to the partner at no cost for their use and a royalty stream from sales of the antibody.



3. QED Bioscience will license your antibody product, kit, or reagent for inclusion in our research product catalog. From sales of these products the licensee will receive royalty payments.

For further information on partnering with QED, contact Dr. Eileen Skaletsky, President and CEO at eileen@qedbio.com

QED Bioscience, Inc.
10919 Technology Place, Suite C, San Diego, CA 92127
Phone 800-929-2114 • Fax 858-592-1509
Email info@qedbio.com